Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and progressive disability. Although current therapies have improved clinical outcomes, safer and more effective therapeutic approaches remain needed. Silicon (Si)-based agents have antioxidant and anti-inflammatory properties and have shown beneficial effects in several inflammatory disease models.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiologists — results on vestibular outcomes are not yet established from this description; audiologists managing vestibular complaints in RA patients should await peer-reviewed outcomes data before altering referral or treatment pathways.
Autoimmune diseases like rheumatoid arthritis are increasingly linked to vestibular dysfunction, and effective systemic treatments targeting both conditions could reduce the burden on audiology and vestibular rehabilitation services.
- 01Study evaluates a silicon-based agent in rheumatoid arthritis (RA) patients who also have vestibular impairment.
- 02Vestibular impairment is a recognized but underappreciated complication of chronic autoimmune disease.
- 03Published in PLoS ONE, an open-access peer-reviewed journal.
- 04Addresses a dual-burden population: inflammatory joint disease plus inner-ear balance disruption.
- 05Findings could inform multidisciplinary management of RA with vestibular complications.
A silicon-based agent is efficacious in treating rheumatoid arthritis patients with complicating vestibular impairment.
studyunclear- PMID
- 42993734
- DOI
- 10.1371/journal.pone.0361954.
- Journal
- PLOS ONE
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Patients with rheumatoid arthritis and complicating vestibular impairment
- Intervention
- Silicon (Si)-based agent
Primary outcomes
Efficacy of Si-based agent on rheumatoid arthritis symptoms; Improvement in vestibular impairment outcomes